NAPLEX Practice Question # 29

NAPLEX Examination.

Practice Question # 29.


 

 

Naplex

Felbamate (Felbatol) NAPLEX Review

Mechanism of action.

A proposed mechanism of action is that the drug interacts with glycine modulatory site on N-methyl-d-aspartate (NMDA) receptors. Blockade of NMDA may contribute to neuroprotective eff ects of felbamate. Felbamate is used as monotherapy or adjunctive therapy or without secondary generalization in adults and generalized seizures associated with Lennox–Gastaut syndrome in children. Th e U.S. Food and Drug

 

Adverse eff ects:

  • Contact the physician if signs of infection (e.g., bleeding or bruising) occur.
  • Th is drug has the potential to cause aplastic anemia (bone marrow).
  • Th e patient should be monitored for these toxicities by CBCs and liver function tests weekly or biweekly until discontinuation of any sign of these toxicities occurs.
  • CNS eff ects are insomnia, headache, anxiety, hyperactivity, and fatigue.
  • Cardiovascular eff ects are peripheral edema, vasodilation, hypotension, and hypertension.
  • Ocular eff ects are diplopia and blurred vision.
  • GI eff ects are anorexia, weight decrease, and nausea.
  • Hematological eff ects may include lymphadenopathy, leukopenia, and thrombocytopenia.
  • Metabolic/nutrition eff ects may include hypokalemia and hyponatremia.
  • QT prolongation and torsade de pointes

 

Leave a Reply